

**Day 1: Tuesday 24<sup>th</sup> May**

**Opening keynotes: Looking to the future**

08:45 **Opening remarks: Jessica Robinson**, Project Director, **Advanced Therapies Congress**

08:55 **Introduction from chair: Miguel Forte**, CEO, **Bone Therapeutics**





09:00 **Keynote panel discussion: State of the industry**  
Chair: **Miguel Forte**, CEO, **Bone Therapeutics**  
**Jakob Dupont**, EVP, Head of Global Research & Development, **Atara Biotherapeutics** (virtual)  
**Vicki Coutinho**, VP of Regulatory Affairs and Quality, **GammaDelta Therapeutics**  
**Magali Taiel**, CMO, **GenSight Biologics** (virtual)  
**Roy Baynes**, Senior Vice President, Clinical Research, **Merck, Sharp & Dohme**



09:30 **Keynote panel discussion: mRNA Therapeutics**  
Chair: **Sarfaraz Niazi**, CEO, **RNA Therapeutics**  
**Paolo Martini**, CSO, Rare Diseases, **Moderna**  
**Haiyan Zhou**, Associate Professor, Genetics & Genomic Medicine Dept, **UCL**



10:00 **Panel discussion: Tackling key regulatory challenges in the advanced therapies space**  
Chair: **Miguel Forte**, CEO, **Bone Therapeutics**  
**Janet Glassford**, Senior Quality Assessor, **Medicines and Healthcare Products Regulatory Agency (MHRA)**  
**Yoshiaki Maruyama**, Review Director, Office of Cellular and Tissue-based Products, **Pharmaceuticals and Medical Devices Agency (PMDA), Japan**  
**Klaus Cichutek**, President, **Paul Ehrlich Institute** (virtual)  
**Peter Marks**, Director, Center For Biologics Evaluation and Research (CBER), **FDA** (virtual)



10:30 **Networking break**  
*Start-up pitches, scroll down for agenda*


11:30 **Roundtables**


	<b>Roundtable 1: Staying at the cutting edge of cell and gene therapy</b> <i>Moderator: Heather L. Callahan, EMBA, Entrepreneur in Residence, Gates Center for Regenerative Medicine, University of Colorado Denver</i>	<b>Roundtable 2: Interactions with Regulatory Authorities for SMEs and Academia</b> <i>Moderator: Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma AB</i>	<b>Roundtable 3: Commercial aspects: what you need to know about running a cell therapy company in 2022 &amp; how to stand out</b> <i>Moderators: David Main, President &amp; CEO, Notch Therapeutics</i>	<b>Roundtable 4: Business models for cell and gene therapy for ultra-rare diseases</b> <i>Moderator: Melodie Dupre, Business Development, Genethon</i> <b>Imen Mestiri, Business Development, Genethon</b>	<b>Roundtable 5: Gene editing</b> <i>Moderator: Hansjörg Hauser, Head of Department Gene Regulation and Differentiation, Helmholtz Centre for Infection Research</i>	<b>Roundtable 6: Current state of standards for regenerative medicine and resources for industry</b> <i>Moderator: Dawn Henke, Senior Technical Program Manager, Standards Coordinating Body</i>	<b>Roundtable 7: Tackling large scale regulatory challenges</b> <i>Moderator: Yemisi Corinaldi, Regulatory Strategy Leader &amp; EU Team Lead, Spark Therapeutics</i>
	<b>Roundtable 8: What are the biggest challenges in bringing ATMPs to market?</b>  <i>Moderator: Tyler DeWitt, Executive Director of Innovation, Quality Executive Partners</i>	<b>Roundtable 9: Collaboration between patient groups and industry</b> <i>Moderator: Ron Jortner, Managing Director, Masthead Biosciences</i>	<b>Roundtable 10: Future-Proofing Supply Chain Orchestration</b> <i>Moderator: Kamar Johnson, Business Development Director, Europe, TrakCel</i> 	<b>Roundtable 11: Tackling digital challenges faced by cell and gene therapy companies</b> <i>Moderator: Ian Davies, Business Consultant, Digital Lab Consulting</i> 	<b>Roundtable 12: How do you control the quality of your cell-based therapy?</b> <i>Moderator: Simon Young, Director, Research and Development Centre UK, Sysmex</i> <i>Reserved for Sysmex</i> 	<b>Roundtable 13: Building industry /academic partnerships</b> <i>Moderator: Basma Jeelani, Head, Business and Innovation Group, Translational Research Office, UCL</i>	
12:30	<b>Lunch</b> <i>Start-up pitches, scroll down for agenda</i>						
	<b>Track 1: Evidence, Pricing &amp; Access</b>	<b>Track 2: Gene Modified Cell Therapy</b> Tackling solid tumours	<b>Track 3: Cell Therapy</b>	<b>Track 4: Gene Therapy</b> Next generation of gene therapy	<b>Track 5: Manufacture</b>	<b>Track 6: Patient Delivery</b>	<b>Track 7: Innovation</b>
	<b>Chair: Alexander Natz, Secretary General, European Confederation of Pharmaceutical</b>	<b>Chair: Lawrence Lamb, Executive Vice President / Chief Scientific Officer, In8Bio</b>	<b>Chair: Stefanos Theoharis, CBO, Bone Therapeutics</b>	<b>Chair: Pedro Gonzalez-Alegre, Head of Gene Therapy Research, Spark Therapeutics</b>	<b>Chair: Patrick J. Hanley, Chief and Director, Cellular Therapy Program,</b>	<b>Chair: Lior Raviv, CTO, Pluristem therapeutics</b>	<b>Chair: Sven Kili, CEO, Antion Biosciences; Principle, Sven Kili Consulting</b>

	<b>Entrepreneurs (EUCOPE)</b>				<b>Children's National Health System</b>		
13:30	<b>Dos and don'ts of launching an ATMP in a European country</b> <b>Alexander Natz</b> , Secretary General, <b>European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)</b>	<b>CAR T-cell immunotherapy of solid tumours: Parallel learning from the clinic and lab</b> <b>John Maher</b> , CSO, <b>Leucid Bio</b>	<b>Harnessing cell death for regenerative medicine</b> <b>Chiara Giacomini</b> , R&D Lead Scientist, <b>King's College London</b>	<b>Shifting gene therapy paradigm with novel capsids and manufacturing processes</b> <b>Fred Chereau</b> , CEO, <b>LogicBio Therapeutics</b> (virtual)	<b>Manufacturing challenges of allogeneic cell medicines – understanding batch-to-batch variation on the way to MAA/BLA</b> <b>Mark Lowdell</b> , CSO, <b>InMune Biotherapeutics</b>	<b>Unleashing the Allogeneic Potential by building solutions for cryologistics</b> <b>Lior Raviv</b> , CTO, <b>Pluristem therapeutics</b>	<b>Multiplex gene engineering, moving beyond editing</b> <b>Sven Kili</b> , CEO, <b>Antion Biosciences</b> ; Principle, <b>Sven Kili Consulting</b>
13:50	<b>Commercialisation of ATMPs (including customer model)</b> <b>Amir Hefni</b> , Vice President and Global Commercial Head for Cell & Gene, <b>Novartis</b>	<b>Harnessing the power of engineered macrophages</b> <b>Tom Wilton</b> , Chief Business Officer, <b>Carisma Therapeutics Inc</b>	<b>Notch signalling for precision cell therapy manufacturing</b> <b>David Main</b> , President & CEO, <b>Notch Therapeutics</b>	<b>Panel discussion: Gene therapy 2.0</b> <b>Chair: Pedro Gonzalez-Alegre</b> , Head of Gene Therapy Research, <b>Spark Therapeutics</b> <b>Pedro Cejas</b> , Discovery Research Lead, <b>Spark Therapeutics</b> <b>Paul Carter</b> , Director, Head Vector Processing, <b>Quell Therapeutics</b>	<b>Shaping the future of Viral Vector Manufacturing using a platform approach</b> <b>Michael Baker</b> , Senior Director Viral Gene Therapy, <b>Fujifilm Diosynth Biotechnologies</b> 	<b>Ten years of evolution, a multifaceted look at modern ATMP orchestration</b> <b>Matthew Lakelin</b> , VP Scientific Affairs and Product Development, <b>TrakCel</b> <i>Sponsored by TrakCel</i> 	<b>Gene Editing &amp; Synthetic biology</b> <b>Hansjörg Hauser</b> , Head of Department Gene Regulation and Differentiation, <b>Helmholtz Centre for Infection Research</b>
14:10	<b>The new EU HTA Regulation, what will be the impact on ATMPs</b> <b>Paolo Morgese</b> , EU Director Market Access & Member Relations, <b>Alliance for Regenerative Medicine</b>	<b>New Directions in the Treatment of Solid Tumors with gdT Cells</b> <b>Lawrence Lamb</b> , Executive Vice President / Chief Scientific Officer, <b>In8Bio</b>	<b>Novel concept for isolators to manufacture ATMPs and Biologics</b> <b>Silvia Aldi</b> , Product Manager for Cell & Gene Therapy, <b>SKAN AG</b> <i>Sponsored by SKAN</i>	<b>Sapan Gandhi</b> , Founder, <b>Drishti Discoveries</b> <b>Bodil Wilumsen</b> , Head of EU Supplier Relationship Team, Cell & Gene Technical Operations, <b>Novartis Pharma</b>	<b>Manufacturing genetically modified NK cells</b> <b>Volker Huppert</b> , Chief Development Officer, <b>Glycostem</b>	<b>The Quality Chain for Receipt, Processing/Manufacturing and Distribution of Cellular Products</b> <b>Tara Sadeghi</b> , EVP and Head of Operations, <b>Cellenkos, Inc</b>	<b>Generic mRNA Vaccine—Scientific, Regulatory and Legal Resolutions—an Advice to Developing Nations</b> <b>Sarfaraz Niazi</b> , CEO, <b>RNA Therapeutics</b>

			<b>skan</b>				
14:30	<p><b>English market presentation/panel: what the future of ATMP landscape might look like</b>  <b>Chair: Nina Pinwill</b>, Head of Commercial Operations, <b>NHS England</b>  <b>Janet Glassford</b>, Senior Quality Assessor, <b>Medicines and Healthcare Products Regulatory Agency (MHRA)</b>  <b>Sheela Upadhyaya</b>, Rare Diseases &amp; RAPID- C19 Strategic Advisor, <b>NICE</b></p>	<p><b>Engineering NK Cell Resistance to the Tumor Microenvironment</b>  <b>Russell Cruz</b>, Assistant Professor, <b>Children's National Medical Center</b>; Co-Founder, <b>Mana Therapeutics</b></p>	<p><b>Phase 3 clinical updates from a personalized vaccine platform technology for cancer and COVID-19</b>  <b>Hans S. Keirstead</b>, Chairman and Chief Executive Officer, <b>AIVITA Biomedical</b></p>	<p><b>Panel discussion: Immunogenicity for gene therapy</b>  <b>Chair: Paul Gissen</b>, Professor of Metabolic Medicine, Head of Genetics and Genomic Medicine Department, <b>UCL Great Ormond Street Institute of Child Health</b>  <b>Sean Armour</b>, Head of Discovery, <b>Spark Therapeutics</b></p>	<p><b>Phase dependent approaches to the supply and testing of materials for advanced therapies</b>  <b>Tony Hitchcock</b>, Technical Director Cell and Gene Therapy CDMO, <b>Charles River Labs</b></p> <p></p>	<p><b>Mastering the orchestration of Cell &amp; Gene Therapy Supply</b>  <b>Andreas Olpeter</b>, Vice President Sales &amp; Business Development, <b>Arvato Supply Chain Solutions – Healthcare</b></p> <p>  <b>BERTELSMANN</b>  Supply Chain Solutions</p>	<p>Presentation  <b>Anthony Johnson</b>, Co-founder and CEO, <b>Kodikaz</b></p>
14:50	<p><b>Panel: Innovative approaches to accelerate access and reimbursement in ATMPs</b>  <b>Chair: Alexander Natz</b>, Secretary General, <b>European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)</b>  <b>Amir Hefni</b>, Vice President and Global</p>	<p><b>Oncolytic viral immunotherapy as a new modality to treat solid tumor</b>  <b>Paul Peter Tak</b>, President &amp; Chief Executive Officer, <b>Candel Therapeutics</b></p>	<p><b>Regenerative Medicine: Challenges in Clinical Translation &amp; the RegmedXB platform</b>  <b>Frank Luyten</b>, Medical/Scientific Director, <b>REGMEDXB</b></p>	<p><b>The re-dosing challenge: redosing strategies</b>  <b>Sean Armour</b>, Head of Discovery, <b>Spark Therapeutics</b></p>	<p><b>BOOSTB4 trial update</b>  <b>Cecilia Götherström</b>, Associate Professor, Department of Clinical Science, Intervention &amp; Technology, <b>Karolinska Institutet</b> (virtual)</p>	<p><b>Panel: Impact of the pandemic on ATMP supply chains and future strategies for improvement</b>  <b>Chair: Jasmin Kee</b>, Bioprocessing Consultant and Former Technical Director, <b>UK Gov Vaccines Taskforce</b>  <b>Sue Williams</b>, Former Head of Supply Chain, <b>UK Gov Vaccines</b></p>	<p><b>Developing the next generation of complement medicines</b>  <b>Rafiq Hasan</b>, CEO, <b>Complement Therapeutics</b></p>
15:10	<p><b>Confederation of Pharmaceutical Entrepreneurs (EUCOPE)</b>  <b>Amir Hefni</b>, Vice President and Global</p>	<p><b>Precise and Efficient Non-viral CRISPR Gene Editing Solutions for T Cell Engineering</b></p>	<p><b>Improving the Digital Landscape at Quell Therapeutics</b>  <b>Julien Browne</b>, Associate Director Head Analytical</p>	<p><b>Fetal gene therapy</b>  <b>Simon Waddington</b>, Professor of Gene Therapy, <b>UCL</b> (possibly virtual)</p>	<p><b>Panel: Standardisation of cell therapy manufacturing</b>  <b>Chair: Patrick J. Hanley</b>, Chief and</p>	<p><b>Multifaceted potential of Treg-based therapies in tackling neurodegeneration</b>  <b>Timothy Newton</b>,</p>	

	<p>Commercial Head for Cell &amp; Gene, <b>Novartis</b></p> <p><b>Mike Fraser</b>, General Manager of EMEA, <b>Novartis Gene Therapies</b></p> <p><b>Detlev Parow</b>, prev Head Pharmaceutical Department, <b>DAK-Gesundheit</b></p> <p><b>Thomas Mueller</b>, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, <b>Federal Ministry of Health Germany</b></p>	<p><b>Raymond Miller</b>, Lead of Global Product Management Team 1, <b>GenScript</b></p> <p><i>Sponsored by GenScript</i></p> 	<p>Development, <b>Quell Therapeutics</b></p> <p><b>Lylia Ouboussad</b>, Senior Scientist, <b>Quell Therapeutics</b></p>  <p><i>Sponsored by Digital Lab Consulting</i></p>		<p>Director, Cellular Therapy Program, <b>Children's National Health System</b></p> <p><b>Mary Murphy</b>, PI and Professor in Regenerative Medicine, <b>REMEMI</b></p> <p><b>Sumona Sarkar</b>, Biomedical Engineer, <b>National Institute of Standards and Technology (NIST)</b> (virtual)</p>	<p><b>Taskforce</b></p> <p><b>Albert Ribickas</b>, Bone Marrow Transplant Laboratory Manager, <b>Moffitt Cancer Center</b></p> <p><b>Lior Raviv</b>, CTO, <b>Pluristem therapeutics</b></p>	<p>CEO, <b>Reflection Therapeutics</b></p>
15:30	<p><b>Networking break</b></p> <p><b>Meet the start-ups! We have 100 start-ups joining us this year, please make your way to the start-up area where they'll be looking forward to meeting you.</b></p>						
	<b>Track 1: Evidence, Pricing &amp; Access</b>	<b>Track 2: Gene Modified Cell Therapy</b> Tackling solid tumours	<b>Track 3: Cell Therapy</b>	<b>Track 4: Gene Therapy</b> Next generation of gene therapy	<b>Track 5: Manufacture</b> Cell therapy manufacture	<b>Track 6: Patient Delivery</b>	
	<b>Chair: Alexander Natz</b> , Secretary General, <b>European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)</b>	<b>Chair: Lawrence Lamb</b> , Executive Vice President / Chief Scientific Officer, <b>In8Bio</b>	<b>Chair: Stefanos Theoharis</b> , CBO, <b>Bone Therapeutics</b>	<b>Chair: Pedro Gonzalez-Alegre</b> , Head of Gene Therapy Research, <b>Spark Therapeutics</b>	<b>Chair: Patrick J. Hanley</b> , Chief and Director, Cellular Therapy Program, <b>Children's National Health System</b>	Chair: <b>Lior Raviv</b> , CTO, <b>Pluristem therapeutics</b>	
16:00	<b>Tissue Engineering – Lessons learnt from the last 15 years</b> <b>Andre Roeder</b> , Head Global Market Access, Head Logistics, <b>TETEC</b> <b>Alexander Natz</b> , Secretary General, <b>European Confederation of</b>	<b>Myeloid programming, the next generation of immune therapies for oncology</b> <b>Daniel Getts</b> , CEO and Co-Founder, <b>Myeloid Therapeutics</b>	<b>Logistical implications of global cell-based therapies for diabetic kidney disease: early phase III lessons learned</b> <b>diabetic kidney disease</b> <b>Joseph Stavas</b> , Senior Vice President of Clinical Development, <b>ProKidney</b>	<b>New Adverse Event terminology for in utero advanced prenatal therapies</b> <b>Anna David</b> , Professor and Consultant in Obstetrics and Maternal Fetal Medicine; Director, EGA Institute for	<b>Evolving choices for cell and gene therapy process development</b> <b>Manuel Carrondo</b> , Professor of Chemical & Biochemical Engineering, FCT-UNL, Vice-President, <b>IBET</b>	<b>Developing an Ideal CAR-T Cell Therapy Patient Experience Through Human Centered Design and Innovation</b> <b>Allison Matthews</b> , Design Lead, <b>Mayo Clinic</b> (virtual) <b>Nancy Pick</b> , Implementation	

	<b>Pharmaceutical Entrepreneurs (EUCOPE)</b>			Women's Health, <b>University College London</b>		Coordinator, <b>Mayo Clinic</b> (virtual)
16:20	<b>Panel: Early detection and screening for genetic diseases and genetic risk factors</b> <b>Chair: Mareike Ostertag</b> , Global Head, Policy Strategy, <b>Novartis Pharma</b> <b>Johan Prévot</b> , Executive Director, <b>IPOPI</b> <b>Jim Bonham</b> , President, <b>International Society for Neonatal Screening</b> <b>Matthew Brown</b> , Chief Scientist, <b>Genomics England</b>	<b>Panel discussion: Moving from liquid to solid tumours</b> <b>Chair: Lawrence Lamb</b> , Executive Vice President / Chief Scientific Officer, <b>In8Bio</b> <b>Patrick J. Hanley</b> , Chief and Director, Cellular Therapy Program, <b>Children's National Health System</b> <b>Daniel Getts</b> , CEO and Co-Founder, <b>Myeloid Therapeutics</b>	<b>Transforming Incubator of Life into Innovative Treatments: allogeneic Amnion Epithelial Stem Cells to treat congenital and chronic disorders without immunosuppression</b> <b>Roberto Gramignoli</b> , Senior Researcher Specialist, <b>Karolinska Institutet</b>	<b>Conjugated AAV platform with current applications in CNS/Ocular</b> <b>Rodolphe Clerval</b> , Chief Executive Officer, <b>Coave Therapeutics</b>	<b>GMP-compliant Manufacturing of MSCs with a Xeno-free Cell culture medium in a closed-system automated bioreactor</b> <b>Lenart Girandon</b> , Deputy Director, <b>Educell</b> <i>Sponsored by VivaBioCell</i> 	<i>Presentation by Cell and Gene Therapy Catapult</i>
16:40	<b>Catherine Joynson</b> , Assistant Director, <b>Nuffield Council on Bioethics</b>	<b>Paul Peter Tak</b> , President & Chief Executive Officer, <b>Candel Therapeutics</b>	<b>Panel discussion: Improving standards for regenerative medicine</b> <b>Chair: Stefanos Theoharis</b> , CBO, <b>Bone Therapeutics</b> <b>Dawn Henke</b> , Senior Technical Program Manager, <b>Standards Coordinating Body</b> <b>Frank Luyten</b> , Medical/Scientific Director, <b>RegMedXB</b>	<b>Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy</b> <b>Magali Taiel</b> , CMO, <b>GenSight Biologics</b> (virtual)	<b>Cost of goods and commercialisation analysis for cell and gene therapies</b> <b>Suzanne S. Farid</b> , Professor of Bioprocess Systems Engineering & Co-Director Future Targeted Healthcare Manufacturing Hub, <b>UCL</b>	<b>Albert Ribickas</b> , Bone Marrow Transplant Laboratory Manager, <b>Moffitt Cancer Center</b> (possible virtual)
17:00	<b>Panel discussion: Is Europe a graveyard for gene therapies?</b> <b>Chair: Sven Kili</b> , CEO, <b>Antion Biosciences</b> ; Principle, <b>Sven Kili Consulting</b> <b>Detlev Parow</b> , prev Head Pharmaceutical			<b>Panel: Emerging safety and regulatory topics in gene replacement therapy</b> <b>Chair: Rajvinder Karda</b> , Lecturer In Gene Therapy, Institute for Women's Health, <b>UCL</b>	<b>Panel discussion: Centralized vs. distributed manufacturing: learnings from current manufacturing</b> <b>Chair: Miriam Haak</b> , Director Business Development, <b>Miltenyi Biotec</b>	


	<p>Department, <b>DAK-Gesundheit</b>  <b>Nicola Redfern</b>, Gene Therapy Commercial Market Access Leader, (Ex General Manager, UK, bluebirdbio)</p> <p><b>Elisabetta Zanon</b>, Director, European Policy and Advocacy, <b>Alliance for Regenerative Medicine</b>  <b>Michela Gabaldo</b>, Head of Translational Project Management &amp; Regulatory Affairs, <b>Fondazione Telethon</b>  <b>Seren Phillips</b>, Health Economics &amp; Outcomes Research, <b>Novartis</b></p>			<p><b>Magali Taiel</b>, CMO, <b>GenSight Biologics</b> (virtual)  <b>Ahad Rahim</b>, Professor of Translational Neuroscience &amp; Head of Research Department of Pharmacology, <b>UCL</b>  <b>Sean Armour</b>, Head of Discovery, <b>Spark Therapeutics</b></p>	<p><b>Farid Ighemat</b>, Senior Director Cell and Gene Therapy, <b>GSK</b>  <b>Dorothea Ledergerber</b>, Chief Technical Officer, <b>TIGEN Pharma</b></p>  <p><b>Miltenyi Biotec</b>  Sponsored by Miltenyi Biotec</p>	
17:30	<b>Day 1 Networking drinks reception</b>					




**Start-up Agenda Tuesday 24<sup>th</sup> May**


10:30	Deana Mohr, CEO & Co-Founder <b>MUVON Therapeutics</b>	<i>Regenerative medicine in daily life: will the dream become reality?</i>
10:45	Pedro Correa de Sampaio, CEO & Co-Founder <b>Neobe Therapeutics</b>	<i>Removing microenvironmental barriers to cancer immunotherapy success through engineered bacteria</i>
11:00	Hans Kleine-Brüggeney, CTO & Co-Founder <b>evorion biotechnologies</b>	<i>Functional phenomics enabling comprehensive analysis of cancer-immune cell interactions at single-cell resolution</i>
11:15	Paulo Refinetti, CEO & Founder <b>REM Analytics</b>	<i>Advanced microbiome analysis and personalised medicine</i>
12:30	Alessia Baldo, Business Development Manager <b>SEED Biosciences</b>	<i>Combining magnetic cell separation with DispenCell for gentle and simple T cell cloning</i>
12:45	Bastiaan Bijl, Head of Business Development, <b>Single Cell Discoveries</b>	<i>Complete single-cell sequencing services</i>
13:00	Poulami Chaudhuri, CEO & Co-founder <b>Helix Bio</b>	<i>Enhanced safety of gene-editing pipelines through tissue-specific gRNAs that enable better control of gene-editing</i>
13:15	Ivo Timmermans, CEO <b>Pleco Therapeutics</b>	<i>New insights into the role of metals in disease</i>







<b>Day 2: Wednesday 25<sup>th</sup> May 2022</b>							
<b>Opening keynotes: State of the industry</b>							
09:00	<b>Keynote panel: Current approaches to advanced cell and gene therapies and (related) adverse events; the Risk - Benefit balance</b> <b>Chair: Jaap Boelens</b> , Chief, Transplantation and Cellular Therapies, MSK Kids, <b>Memorial Sloan Kettering Cancer Center</b> <b>Florian Eichler</b> , Neurologist, <b>Massachusetts General Hospital</b> <b>Matthew Porteus</b> , Professor of Pediatrics, <b>Stanford University School of Medicine</b> (virtual) <b>Paul Orchard</b> , Professor, Department of Pediatrics, <b>University of Minnesota</b> (possibly virtual)						
09:30	<b>Panel discussion: Addressing the skill shortage in Advanced Therapies</b> <b>Chair: Qasim Rafiq</b> , Associate Professor in Cell and Gene Therapy Bioprocess Engineering, <b>UCL</b> <b>Sven Killi</b> , CEO, <b>Antion Biosciences</b> <b>Jasmin Kee</b> , Bioprocessing Consultant and Former Technical Director, <b>UK Gov Vaccines Taskforce</b> <b>James Miskin</b> , CTO, <b>Oxford Biomedica</b> <b>Russell Cruz</b> , Principal Investigator, Cell-Based Immunotherapies for Cancer and HIV, <b>Children’s National Hospital</b>						
10:00	<b>Panel discussion: Deals and investments made: where are we going in 2023?</b> <b>Chair: Sven Kili</b> , CEO, <b>Antion Biosciences</b> ; Principle, <b>Sven Kili Consulting</b> <b>Owen Smith</b> , Partner, <b>4BIO Capital</b> <b>Daniel O’Mahony</b> , Partner, <b>Seroba Life Sciences</b> <b>Dominic Schmidt</b> , General Partner, <b>Advent Life Sciences</b> <b>Dave Greenwald</b> , Vice President Of Business Development, <b>Deerfield Management</b> <b>Simon Goldman</b> , Investment Director, UCL Technology Fund, <b>Albion VC</b>						
10:30	<b>Networking break</b> <i>Poster viewing session &amp; start-up pitches, scroll down for agenda</i>						
	<b>Track 1: Evidence, Pricing &amp; Access</b>	<b>Track 2: Gene Modified Cell Therapy</b>	<b>Track 3: Cell Therapy</b>	<b>Track 4: Gene Therapy</b>	<b>Track 5: Manufacture</b>	<b>Track 6: Cord blood and tissue</b>	<b>Track 7: Innovation</b>
	<b>Chair: Yemisi Corinaldi</b> , Regulatory Strategy Leader & EU Team Lead, <b>Spark Therapeutics</b>	<b>Chair: Peter Olagunju</b> , CTO, <b>TCR2</b>	<b>Chair: Miguel Forte</b> , CEO, <b>Bone Therapeutics</b>	<b>Chair: Eric Michael David</b> , CEO, <b>Gene Therapy BridgeBio</b>	<b>Chair: Patrick J. Hanley</b> , Chief and Director, Cellular Therapy Program, <b>Children's National Health System</b>	<b>Chair: Moshe Israeli</b> , Medical Director, <b>Rabin Medical Center</b>	<b>Chair: David Morrow</b> , Senior Scientific Programme Manager-ATMP/Vaccines, <b>EATRIS</b>
11:00	<b>What does it take to put a gene therapy into the clinic?</b>	<b>Towards Individualized</b>	<b>ISCT: Trends in CGT Translation</b>	<b>Leveraging Moderna’s mRNA platform in the</b>	<b>Process intensification and manufacturing</b>	<b>Moshe Israeli</b> , Medical Director,	<b>Optimising gene therapy translation</b>

	<b>Séverine Marconi</b> , EU Senior Director, Regulatory Affairs, <b>AskBio</b>	<b>Lymphodepletion for CAR-T/Cell therapies to improve outcomes</b> <b>Jaap Boelens</b> , Chief, Transplantation and Cellular Therapies, MSK Kids, <b>Memorial Sloan Kettering Cancer Center</b>	<b>Miguel Forte</b> , President Elect, <b>ISCT</b> ; CEO, <b>Bone Therapeutics</b>	<b>context of rare diseases</b> <b>Paolo Martini</b> , CSO, Rare Diseases, <b>Moderna</b>	<b>strategies for ATMPs</b> <b>Qasim Rafiq</b> , Associate Professor in Cell and Gene Therapy Bioprocess Engineering, <b>UCL</b>	<b>Rabin Medical Center</b>	<b>from academia to industry</b> <b>Pamela Tranter</b> , Head, Translational Research Group, Translational Research Office, <b>UCL</b>
11:20	<b>Panel discussion: Getting first in class therapies into the clinic</b> <b>Chair: Yemisi Corinaldi</b> , Regulatory Strategy Leader & EU Team Lead, <b>Spark Therapeutics</b> <b>Séverine Marconi</b> , EU Senior Director, Regulatory Affairs, <b>AskBio</b>	<b>Expanding CAR T cell profiling to accelerate therapeutic insights</b> <b>Greg Hopkins</b> , Associate Manager/Scientist, Analytical Development Group, <b>Zseventy bio</b>	<b>3D cultivation of mesenchymal stem cells</b> <b>Cornelia Kasper</b> , Professor, Biopharmaceutical Production & Technology, <b>BOKU</b>	<b>Genethon: late preclinical and clinical updates</b> <b>Melodie Dupre</b> , Business Development, <b>Genethon</b> <b>Imen Mestiri</b> , Business Development, <b>Genethon</b>	<b>Workforce education as advanced as ATMP's: Navigating the talent shortage</b> <b>Tyler DeWitt</b> , Executive Director of Innovation, <b>Quality Executive Partners</b> 	<b>Use of cord blood as starting material for cell therapy</b> <b>Marcie Finney</b> , Executive Director <b>Cleveland Cord Blood Center</b>	<b>UK Gene Therapy Innovation Hub: Optimising translation from academia to industry</b> <b>Sven Kili</b> , CEO, <b>Antion Biosciences</b> ; Principle, <b>Sven Kili Consulting</b>
11:40	<b>Tom Wilton</b> , Chief Business Officer, <b>Carisma Therapeutics Inc</b> <b>Vicki Coutinho</b> , VP of Regulatory Affairs and Quality, <b>GammaDelta Therapeutics</b>	<b>TCR<sup>2</sup>: An autologous approach to addressing solid tumors</b> <b>Peter Olagunju</b> , CTO, <b>TCR2</b>	<b>Mesenchymal stromal cells - an unlimited source of cell therapies</b> <b>Andre Gerth</b> , CEO, <b>Famicord Germany</b>	<b>Panel discussion: Rare diseases &amp; orphan drugs, patient perspectives</b> <b>Chair: Ron Jortner</b> , Managing Director, <b>Masthead Biosciences</b> <b>David Rose</b> , Business Development, <b>Rare Revolution Magazine</b> <b>Daniel Lewi</b> , Co- Founder, <b>Cure and</b>	<b>Scalable Purification of Recombinant Adeno-Associated Viral Vectors</b> <b>Emmanuelle Cameau</b> , Strategic Technology Partnership Leader, <b>Pall Corporation</b> <i>Sponsored by Pall</i>	<b>Experimental approaches to improve umbilical cord blood transplant outcomes</b> <b>Omar Aljitawi</b> , Associate Professor, <b>University of Rochester Medical Center</b> (virtual)	<b>The role of Research Infrastructures in supporting Innovative Vaccine and ATMP development to tackle infectious diseases and cancer</b> <b>David Morrow</b> , Senior Scientific Programme Manager- ATMP/Vaccines, <b>EATRIS</b>

				<p><b>Action for Tay Sachs (CATS) Foundation;</b>  Head, Patient Advocacy, <b>Pulse Inframe</b>  <b>Elizabeth Johnson,</b>  Co-Founder,</p>			
12:00	<p><b>Current status on cell and gene therapy in Japan</b>  <b>Yoshiaki Maruyama,</b>  Review Director,  Office of Cellular and Tissue-based Products,  <b>Pharmaceuticals and Medical Devices Agency (PMDA), Japan</b></p>	<p><b>Panel discussion: Autologous vs allogeneic</b>  <b>Chair: Peter Olagunju, CTO, TCR2</b>  <b>Jaap Boelens,</b> Chief, Transplantation and Cellular Therapies, MSK Kids, <b>Memorial Sloan Kettering Cancer Center</b>  <b>Gregory Fiore,</b> CEO <b>Exacis Biotherapeutics</b>  <b>Vicki Coutinho,</b> VP of Regulatory Affairs and Quality, <b>GammaDelta Therapeutics</b></p>	<p><b>Measuring biodistribution of cell therapies in humans and other species</b>  <b>Mangala Srinivas,</b> Professor and Head of Cell Biology and Immunology, <b>Wageningen University and Research;</b> CSO, <b>Kenya Imaging</b></p>	<p><b>National Association of Medication Access &amp; Patient Advocacy</b> (possibly virtual)</p>	<p><b>A single platform for Cell Therapy manufacturing from research to commercial. Dream or reality?</b>  <b>Marco Fadda,</b> ATMP Solutions Manager  <b>Comecer</b>  </p>	<p><b>Promoting best practice in cord blood utilisation through collaboration</b>  <b>Roger Horton,</b> Cell and Gene Therapies Clinical Delivery Lead,  <b>Anthony Nolan</b></p>	<p><b>New approaches for identification of potential off-target mutations associated with genome editing in cell therapies – a collaborative initiative</b>  <b>Mick Fellows,</b> Director CVRM Cell Therapy Safety Clinical Pharmacology and Safety Sciences, <b>AstraZeneca</b></p>
12:20	<p><b>Panel discussion: Ask the investors</b>  <b>Chair: Sven Kili,</b> CEO, <b>Antion Biosciences</b>  <b>Owen Smith,</b> Partner, <b>4BIO Capital</b>  <b>Daniel O’Mahony,</b> Partner, <b>Seroba Life Sciences</b>  <b>Dominic Schmidt,</b> General Partner, <b>Advent Life Sciences</b></p>		<p><b>Treating cancer and covid with allogenic gamma delta T cells, update on phase 2/3 clinical programs</b>  <b>Michael Leek,</b> Executive Director, <b>TC Biopharm</b></p>	<p><b>Building a next gen gene editing toolbox</b>  <b>Devyn Smith,</b> CEO, <b>Arbor Biotechnology</b></p>	<p><b>Metabolic and Environmental Control-Based Automation, Machine Learning and AI with the Adva X3 Platform</b>  <b>Ohad Karnieli,</b> CEO, <b>Adva Biotechnology</b>  <i>Reserved for Adva Biotechnology</i>  </p>	<p><b>Allogeneic UC-MSC drug product for treatment of type 1 diabetes</b>  <b>Mathias Svahn,</b> CEO and Co-Founder, <b>NextCell Pharma AB</b></p>	<p><b>The development of new T-cell based concepts for cancer immunotherapy</b>  <b>Even Holth Rustad,</b> Researcher; <b>Oslo University Hospital</b> (confirmed)</p>

12:40	<p><b>David Greenwald</b>, Vice President of Business Development, <b>Deerfield Management</b></p> <p><b>Simon Goldman</b>, Investment Director, UCL Technology Fund, <b>Albion VC</b></p>		<p><b>Current and in development standards for advanced therapies</b></p> <p><b>Dawn Henke</b>, Senior Technical Program Manager, <b>Standards Coordinating Body</b></p>	<p><b>Gene therapy in neurology: de-risking trials by knowing disease biology</b></p> <p><b>Florian Eichler</b>, Neurologist, <b>Massachusetts General Hospital</b></p>	<p><b>ATMP Quality Control: Supporting Your GMP Goals</b></p> <p><b>Rey Mali</b>, VP, Sales, Marketing and Support, <b>Accellix</b></p>  <p><i>Sponsored by Accellix/Biomerieux</i></p>	<p><b>Manufacturing stem cell therapies at cord blood bank.</b></p> <p><b>FamiCord experience</b></p> <p><b>Tomasz Baran</b>, Executive VP, <b>PBKM/FamiCord Group</b></p>	<p><b>Automating autologous and allogeneic cell therapy manufacturing</b></p> <p><b>Laura Herbst</b>, Research Fellow, <b>Fraunhofer Institute for Production Technology IPT</b></p>
13:00	<p><b>Lunch</b></p> <p><i>Start-up pitches, scroll down for agenda</i></p>						
	<b>Track 1: Evidence, Pricing &amp; Access</b>	<b>Track 2: Immunology</b>	<b>Track 3: Cell Therapy</b>	<b>Track 4: Gene Therapy</b>	<b>Track 5: Manufacture</b> Continuous integrated bioprocessing	<b>Track 6: Cord blood and tissue</b>	<b>Track 7: Innovation</b>
	<p><b>Chair: Yemisi Corinaldi</b>, Regulatory Strategy Leader &amp; EU Team Lead, <b>Spark Therapeutics</b></p>	<p><b>Chair: Roy Baynes</b>, Senior Vice President, Clinical Research, <b>Merck, Sharp &amp; Dohme</b></p>	<p><b>Chair: Miguel Forte</b>, CEO, <b>Bone Therapeutics</b></p>	<p>Chair: <b>Eric Michael David</b>, CEO, <b>Gene Therapy BridgeBio</b></p>	<p><b>Chair: Patrick J. Hanley</b>, Chief and Director, Cellular Therapy Program, <b>Children's National Health System</b></p>	<p>Chair: <b>Moshe Israeli</b>, Medical Director, <b>Rabin Medical Center</b></p>	<p><b>Chair: Sven Kili</b>, CEO, <b>Antion Biosciences</b>; Principle, <b>Sven Kili Consulting</b></p>
14:00	<p><b>Common pitfalls and hurdles when reaching registration and market access for a new next generation therapeutic</b></p>	<p><b>Building on what we've seen so far: combinations</b></p> <p><b>Jon Cheng</b>, SVP, Head of Oncology Development, <b>Bristol Myers Squibb</b></p>	<p><b>Clinical development of iPSC-derived mesenchymal stem cells</b></p> <p><b>Ross Macdonald</b>, Managing Director and Chief Executive</p>	<p><b>Gene therapy for non-genetic neurological disorders: What is the promise? What are the challenges?</b></p>	<p><b>Addressing gene therapy commercialization bottlenecks through intensified and integrated manufacturing</b></p>	<p><b>Cord Blood and Cord Tissue Therapies for Children</b></p> <p><b>Joanne Kurtzberg</b>, Professor of Pediatrics &amp; Pathology; Director,</p>	<p><b>Little, useful secrets on how to create and execute an effective quantum computing strategy</b></p> <p><b>Fausto Artico</b>, Global R&amp;D Tech Head and</p>

	<b>Michela Gabaldo</b> , Head of Translational Project Management & Regulatory Affairs, <b>Fondazione Telethon</b>		Officer, <b>Cynata Therapeutics</b>	<b>Rajvinder Karda</b> , Lecturer In Gene Therapy, Institute for Women's Health, <b>UCL</b>	<b>Thomas Robert</b> , Product Manager, <b>Univercells Technologies</b> 	Marcus Center for Cellular Cures, <b>Duke University Medical Center</b> (virtual)	Director of Innovation and Data Science, <b>GSK</b>
14:20	<b>Panel: What is the value of existing real-world databases? How reliable are health databases?</b> <b>Chair: Yemisi Corinaldi</b> , Regulatory Strategy Leader & EU Team Lead, <b>Spark Therapeutics</b>	<b>Precision medicine informed therapeutic approaches to synthetic lethality</b> <b>Simon Hollingsworth</b> , VP, Global Product Leader – Lynparza, <b>AstraZeneca</b>	<b>Impact of the COVID-19 pandemic on clinical trials in advanced cell therapy</b> <b>Frances Verter</b> , CEO, <b>CellTrials.org &amp; Parent's Guide to Cord Blood</b>	<b>Panel discussion: Philanthropic VC perspective for rare diseases</b> Chair: <b>Eric Michael David</b> , CEO, <b>Gene Therapy BridgeBio</b> <b>Dave Greenwald</b> , Vice President Of Business	<b>Moving from observing effects in process development to understanding them</b> <b>Christoph Herwig</b> , Professor of Biochemical Engineering, <b>Vienna University of Technology</b>	<b>Panel discussion: The changing landscape of Cord blood banking environment</b> Chair: <b>Moshe Israeli</b> , Medical Director, <b>Rabin Medical Center</b> <b>Joanne Kurtzberg</b> , Professor	<b>Advancement of Cell Replacement Therapy</b> <b>Harald Stover</b> , Founder, CEO & CTO, <b>Allarta Life Sciences</b>
14:40	<b>Sheela Upadhyaya</b> , Rare Diseases & RAPID-C19 Strategic Advisor, <b>NICE</b> <b>Fausto Artico</b> , Global R&D Tech Head and Director of Innovation and Data Science, <b>GSK</b> <b>Michela Gabaldo</b> , Head of Translational Project Management & Regulatory Affairs, <b>Fondazione Telethon</b>	Next Generation Immuno-oncology <b>David Fontana</b> , Chief Business and Strategy Officer, <b>Umoja Biopharma</b>	<b>Consistency and dependability of quality testing for clinical grade induced pluripotent stem cells</b> <b>Stephen Sullivan</b> , Program Manager & International Liaison Officer, <b>Global Alliance for iPSC Therapies (GAiT)</b>	Development, <b>Deerfield Management</b> <b>Javier Garcia</b> , CEO, <b>Viralgen</b> <b>Mark Veich</b> , Executive Director, <b>Deerfield Foundation</b> , <b>Deerfield Management</b>  <b>Bruno Montanari</b> , Partner, <b>Seroba Life Sciences</b>	<b>Navigating the challenges of AAV process development and manufacturing</b> <b>Yatindra Tirunagari</b> , Head of Process Development, <b>Rentschler, ATMP</b> <b>Lucia Kirchgeorg</b> , Director Business Development, <b>Rentschler Biopharma</b>	of Pediatrics & Pathology; Director, Marcus Center for Cellular Cures, <b>Duke University Medical Center</b> (virtual) <b>Roger Horton</b> , Cell and Gene Therapies Clinical Delivery Lead, <b>Anthony Nolan</b> <b>Marcie Finney</b> , Executive Director <b>Cleveland Cord Blood Center</b> <b>Tomasz Baran</b> ,	<b>Driving the advanced therapy processing revolution; a biocomputer based therapy development kit</b> <b>Colin Barker</b> , Chief Scientific Officer & Co-founder, <b>Biologic Technologies</b>  <i>Sponsored by</i> <i>Biologic Technologies</i> 

					<p>Sponsored by Rentschler Biopharma</p> 	<p>Executive VP, PBKM/FamiCord Group</p>	
15:00	<p><b>Panel discussion: Creating a collaborative ecosystem</b> <b>Chair: Yemisi Corinaldi</b>, Regulatory Strategy Leader &amp; EU Team Lead, <b>Spark Therapeutics</b> <b>Devyn Smith</b>, CEO, <b>Arbor Biotechnology</b> <b>David Venables</b>, Founding CEO, <b>Skylark Therapeutics</b> <b>Bodil Willumsen</b>, Head of EU Supplier Relationship Team, Cell &amp; Gene Technical Operations, <b>Novartis Pharma</b></p>	<p><b>Precision medicine informed immuno-oncology</b> <b>Roy Baynes</b>, Senior Vice President, Clinical Research, <b>Merck, Sharp &amp; Dohme</b></p>	<p><b>Decidua stromal cell, as a novel and promising therapeutic cell for acute inflammatory diseases</b>, Behnam Sadeghi, Head of Translational Cell therapy Research (TCR), <b>Karolinska Institute</b></p>	<p><b>Therapeutic platforms for the treatment of monogenic diseases</b> <b>Philip J. Brooks</b>, Program Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), <b>National Institutes of Health</b></p>			<p><b>SCTbio, your reliable CDMO partner for cell &amp; gene therapy GMP manufacturing</b> <b>Pascale Charbonnel</b>, Business Development, <b>SCTbio</b> <i>Reserved for SCTbio</i></p> 
15:20	<p><b>Networking break</b> <i>Start-up pitches, scroll down for agenda</i></p>						
	<b>Track 1: Evidence, Pricing &amp; Access</b>		<b>Track 2: Immuno-oncology</b>		<b>Track 5: Manufacture</b> Continuous integrated bioprocessing		
	<p><b>Chair: Yemisi Corinaldi</b>, Regulatory Strategy Leader &amp; EU Team Lead, <b>Spark Therapeutics</b></p>		<p><b>Chair: Roy Baynes</b>, Senior Vice President, Clinical Research, <b>Merck, Sharp &amp; Dohme</b></p>		<p><b>Chair: Patrick J. Hanley</b>, Chief and Director, Cellular Therapy Program, <b>Children's National Health System</b></p>		

16:00	<p><b>Regulatory session for academic and early-stage companies</b>  <b>Chair: Victoria English</b>, Co-founder &amp; Editor, Evernow Publishing Ltd, publishers of <b>MedNous</b></p>	<p><b>Optimising risk and benefit in immunotherapy of GU malignancies</b>  <b>Timothy Eisen</b>, Professor, Medical Oncology, <b>University of Cambridge</b>; Franchise Head, GU Oncology, <b>Roche</b></p>	<p><b>Implementation of automation &amp; closed systems in a multi-user, multi-product facility</b>  <b>Ben Weil</b>, Head of GMP Process Engineering, Centre for Cell, Gene and Tissue Therapeutics, <b>Royal Free Hospital, NHS Foundation Trust</b></p>
16:20	<p><b>Margareth Jorvid</b>, Head of Regulatory Affairs, <b>Ilya Pharma AB</b>  <b>Vicki Coutinho</b>, VP of Regulatory Affairs and Quality, <b>GammaDelta Therapeutics</b>  <b>Nneka Onwudiwe</b>, Former PRO/PE Regulatory Review Officer, <b>Food and Drug Administration (FDA)</b></p>	<p><b>Panel: Intersection of precision medicine, targeted therapies, and immune oncology</b>  <b>Chair: Roy Baynes</b>, Senior Vice President, Clinical Research, <b>Merck, Sharp &amp; Dohme</b>  <b>Simon Hollingsworth</b>, VP, Global Product Leader – Lynparza, <b>AstraZeneca</b></p>	<p><b>Closed system manufacturing to create a CAR T for brain tumours</b>  <b>Shabnum Patel</b>, Associate Director, Process Development &amp; Manufacturing  Center for Cancer Cell Therapy, <b>Stanford Cancer Institute</b></p>
16:40		<p><b>Jon Cheng</b>, SVP, Head of Oncology Development, <b>Bristol Myers Squibb</b>  <b>Timothy Eisen</b>, Professor, Medical Oncology, <b>University of Cambridge</b>; Franchise Head, GU Oncology, <b>Roche</b>  <b>David Fontana</b>, Chief Business and Strategy Officer, <b>Umoja Biopharma</b></p>	<p><b>Panel: Automation &amp; closed systems</b>  <b>Chair: Patrick J. Hanley</b>, Chief and Director, Cellular Therapy Program, <b>Children’s National Health System</b>  <b>Joan Fitzgerald</b>, Research Fellow, Calin Project, Regenerative Medicine Institute (REMEDI), <b>National University of Ireland Galway</b>  <b>Christoph Herwig</b>, Professor of Biochemical Engineering, <b>Vienna University of Technology</b>  <b>Laura Herbst</b>, Research Fellow, <b>Fraunhofer Institute for Production Technology IPT</b>  <b>Ben Weil</b>, Head of GMP Process Engineering, Centre for Cell, Gene and Tissue Therapeutics, <b>Royal Free Hospital, NHS Foundation Trust</b>  <b>Fausto Artico</b>, Global R&amp;D Tech Head and Director of Innovation and Data Science, <b>GSK</b></p>
17:00	<b>End of conference, see you next year!</b>		

**Start-up Agenda, Wednesday 25<sup>th</sup> May**

10:30	<b>Jean Simon-Diallo</b> , CEO & Scientific Founder <b>Virica Biotech</b>	<i>Maximizing vector production - targeting antiviral defense using small molecule VSEs</i>
10:45	<b>James Kusena</b> , Head of Bioprocessing, <b>MicrofluidX</b>	<i>A novel microfluidics-based platform for process development and manufacture of cell therapies</i>
13:00	<b>Sapan Gandhi</b> , Founder, <b>Drishti Discoveries</b>	<i>RNA-targeting gene therapy for Amyotrophic Lateral Sclerosis</i>
13:15	<b>Adam Inche</b> , Founder and CEO, <b>Lentitek Ltd</b>	<i>Order of Magnitude – a simple change to increase lentiviral production yields by 10 fold</i>
13:30	<b>Philippe Chambon</b> , Chairman & CEO <b>EG 427</b>	<i>Non replicative HSV, next generation vectors for gene therapy</i>
13:45	<b>Laura Koivusalo</b> , CEO & Founder <b>StemSight</b>	<i>Curing corneal blindness with stem cells</i>
15:20	<b>Luka Fajs</b> , CEO & Head of Research <b>Bio-ReCell</b>	<i>Automated and closed system for magnet-free, target cell separation</i>
15:35	<b>Krishna Patel</b> , Partner, <b>Tanya Sharma</b> , Partner, <b>Assurea</b>	<i>Start up quality and compliance: Building the foundation</i>